目的 旨在探讨脑胶质瘤在MRI动 态增强扫描中的图像表现特征及临床应用 价值。方法 选取我院2013年1月-2018年 4月收治的脑胶质瘤患者39例，患者均进 行了MRI检查，收集患者临床资料及影像 学资料，由两名副主任级医师分析并总 结39例脑胶质瘤患者MRI动态增强扫描图 像表现特征，分析MRI动态增强扫描对脑 胶质瘤的临床应用价值。结果 MRI平扫 中胶质瘤实质部分主要表现为长T1、长 T2信号；累及范围：累及范围2个脑叶者 6例，累及范围≥3个脑叶者，39例患者 中，21例患者主要累及颞叶、额叶。16 例低级别胶质瘤患者T1WI呈现低信号，12 例T2WI呈现高信号，9例患者为等信号， T1WI增强扫描中17例患者为结节强化；16 例高级别胶质瘤T1WI表现为低信号，14例 T2WI呈现高信号，T1WI增强扫描中13例 患者为边缘强化；低级别胶质瘤ADC值为 (1.23±0.26)s/mm2 ，明显低于高级别胶 质瘤(0.86±0.14)s/mm2 ，差异具有统计 学意义(t=5.397，P<0.001)。结论 MRI 动态增强扫描可有效显示脑胶质瘤信号特 点、强化特征，多序列扫描结合ADC值可 提高临床评估脑胶质瘤分期的准确性，为 临床制定治疗方案提供可靠资料。

Objective To explore the imaging features and clinical application value of glioma in dynamic enhanced MRI scan. Methods 39 patients with glioma admitted to our hospital from January 2013 to April 2018 were selected. All the patients underwent MRI examination, and the clinical data and imaging data were collected. The imaging features of 39 patients with glioma were analyzed and summarized by two associate chief physicians, and the clinical application value of dynamic enhanced MRI in glioma was analyzed. Results The main manifestations of glioma in MRI were long T1 and long T2 signals. Involvement range: 6 patients with 2 lobes and 3 lobes or greater were involved. Of the 39 patients, 21 were mainly involved in the temporal and frontal lobes. 16 patients with low-grade glioma presented low signal on T1WI, 12 presented high signal on T2WI, 9 presented equal signal, and 17 patients presented nodular enhancement in T1WI enhanced scanning. There were 16 cases of high-grade glioma with low signal on T1WI, 14 cases with high signal on T2WI, and 13 cases with edge enhancement in T1WI enhanced scan. The ADC value of low grade glioma was (1.23±0.26) s/mm2 , significantly lower than that of high grade glioma (0.86±0.14) s/mm2 , and the difference had statistical significance (t=5.397, P<0.001). Conclusion MRI dynamic enhanced scan can effectively display the signal characteristics and enhancement features of glioma, and multiple sequence scanning combined with ADC value can improve the accuracy of clinical evaluation of glioma staging and provide reliable data for clinical treatment planning.